Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss HAE patients and the COVID vaccine. We encourage everyone to please watch this short video that discusses how having HAE
About daphnecanadaThis author has not yet filled in any details.
So far daphnecanada has created 9 blog entries.
We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug Benefit List. Alberta is the first province
Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA)
We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab (Takhzyro) and soon HAE patients in Quebec
Thank you to the amazing HAE Community here in Canada - Canada won the Virtual 2020 HAE Global Walk; an annual event organized by the HAE International team. Many people from different parts of the
HAEGARDA and TAKHZYRO are now available in Canada. Please talk to your HAE specialist about access. Thank you Canadian Blood Services (CBS) for a very collaborative, informative and team building HAE Forum. The care for
We are thrilled to let the HAE community know that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available to HAE patients in Quebec. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for